Vonicog Alfa

Phase 3Biologic

Takeda

Vonicog Alfa is one of 8 biologic programs targeting Von Willebrand disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseRecruiting

Von Willebrand DiseasePhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Von Willebrand Disease

#DrugCompanyPhaseTrials

Advate

Takeda

Phase 3

1 2

Antihemophilic Factor (recombinant)

Takeda

Phase 3

1 3

VGA039

VVega Therapeutics, Inc

Phase 3

1 4

Vonicog Alfa

Takeda

Phase 3

2 5

BT200

BBand Therapeutics

Phase 2

1 6

Recombinant Interferon Alfa 2a

Roche

Preclinical

—7

Activated Prothrombin Complex Concentrate

Roche

Preclinical

—8

Von Willebrand Factor Concentrates

Roche

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Recruiting

Von Willebrand Disease (VWD)

NCT05582993

Q2 2031

Recruiting

Von Willebrand Disease

NCT07404644

Clinical

Trials by Indication[1]

Von Willebrand disease2 trials

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting·BBaxalta now part of Shire·Phase 3·NCT02932618·31 enrolled

An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

Recruiting· Takeda logo

Takeda··NCT07404644·13 enrolled

Von Willebrand Disease (VWD)1 trial

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease

Recruiting· Takeda logo

Takeda·Phase 3·NCT05582993·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vonicog Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vonicog Alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vonicog Alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Takeda

Vonicog Alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q2 2031

Trials by Indication[1]

Von Willebrand disease2 trials

Von Willebrand Disease (VWD)1 trial

References

Drug Info

Quick Facts

Related News